MRLB-223 is a preferential HDAC1 and HDAC2 inhibitor with activity against tumor cells.MRLB-223 induces histone hyperacetylation, intrinsic apoptotic pathway activation, tumor cell apoptosis, Hsp90 hyperacetylation, and caspase-dependent Bcr-Abl degradation.MRLB-223 mediates p53-independent tumor cell death, with activity suppressed by Bcl-2 overexpression, and kills Bcr-Abl-expressing myeloid cells.MRLB-223 exerts effects in mice bearing Eµ-myc lymphomas.MRLB-223 can be used for the research of Eµ-myc lymphoma[1].
Molekulargewicht:
449.53
CAS Nummer:
[937727-03-2]
Formel:
C23H23N5O3S
Target-Kategorie:
Apoptosis,Bcr-Abl,HDAC,HSP
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
